# OnCo record nct02489318 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/nct02489318/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "nct02489318", "NCT02489318" ;
  schema:name "A Study of Apalutamide (JNJ-56021927, ARN-509) Plus Androgen Deprivation Therapy (ADT) Versus ADT in Participants With mHSPC"@en ;
  schema:alternateName "TITAN"@en ;
  schema:description "A phase 3 trial of Apalutamide in prostate cancer, run by Aragon Pharmaceuticals, Inc., active and no longer recruiting."@en ;
  schema:url <https://onco.cc/trials/nct02489318/> ;
  schema:dateModified "2026-09-16"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT02489318>, <https://doi.org/10.1056/NEJMoa1903307>, <https://www.nice.org.uk/guidance/ta741>, <https://www.nice.org.uk/guidance/ta1109> ;
  onco:status "active" ;
  onco:tag "ctgov-ingest" ;
  onco:phase "3" ;
  schema:startDate "2015-11-27" ;
  onco:cancers <https://onco.cc/cancers/prostate/>, <https://onco.cc/cancers/prostate-mhspc/> ;
  onco:technologies <https://onco.cc/technologies/androgen-deprivation/> ;
  onco:drugs <https://onco.cc/drugs/apalutamide/> ;
  onco:companies <https://onco.cc/companies/johnson-johnson/> ;
  onco:trials <https://onco.cc/trials/arches/>, <https://onco.cc/trials/enzamet/>, <https://onco.cc/trials/latitude/>, <https://onco.cc/trials/aranote/>, <https://onco.cc/trials/nct01946204/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-nct02489318-n-engl-j-med-2019/> .